CTOs on the Move

Xenocor

www.xenocor.com

 
Bringing to market revolutionary laparoscopic technologies which extend the benefits of minimally invasive surgery to hundreds of millions of people worldwide.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.xenocor.com
  • 630, Komas Drive
    Salt Lake City, UT USA 84108
  • Phone: 844.936.6267

Executives

Name Title Contact Details

Similar Companies

Montana Health Research Inst

Montana Health Research Inst is a Billings, MT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BTL Industries

Founded in 1993, BTL has grown to become one of the world’s major manufacturers of medical equipment. BTLs major segments include physical therapy, cardiology and medical aesthetics.

DocRx

At DocRX we help doctors and hospitals become more efficient, and profitable. We also help make them compliant with regulations. Visit us today!

Health Solutions Network

Health Solutions Network is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Windtree Therapeutics

Windtree Therapeutics, Inc. is advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders to treat patients in moments of crisis. Using new clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate istaroxime being developed as a first-in-class treatment for acute heart failure and early cardiogenic shock in heart failure. Windtree has also focused on developing AEROSURF® as a non-invasive surfactant treatment for premature infants with respiratory distress syndrome, and is facilitating transfer of clinical development of AEROSURF® to its licensee in Asia, Lee`s HK, while Windtree evaluates other uses for its synthetic KL4 surfactant for the treatment of acute pulmonary conditions including lung injury due to viral, chemical and radiation induced insults. Also, in its portfolio is rostafuroxin, a novel precision drug product targeting hypertensive patients with certain genetic profiles.